Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Q1 2025 Management View CEO Greg Daily highlighted a 12% increase in revenue and a 17% increase in adjusted EBITDA compared to Q1 2024. SaaS revenue grew by 16%, reflecting the company’s focus on ...

One thing we’ve learned while powering subscriptions for over 20,000 brands is that there are a lot of ways to build a ...